jimnyc
08-13-2021, 02:43 PM
Right onto the same avenue that Juicer66 posted about yesterday, this impending Lambda variant coming our way inevitably. Thus far they are claiming that it "could" be vaccine resistant and perhaps our current vaccine of record won't do jack shit for it.
---
Study: Deadly lambda variant could be vaccine-resistant
Researchers sounding alarm on latest COVID mutation
As the United States struggles with the delta variant of the novel coronavirus, a new study finds that vaccines are ineffective against the lambda mutation that is ravaging parts of South America.
Researchers in Japan pointed out that the lambda variant, which first surfaced in Peru about a year ago, surged in Chile in the spring despite a high vaccination rate, the New York Post reported. (https://nypost.com/2021/08/12/deadly-lambda-covid-19-variant-could-be-vaccine-resistant/)
The study awaits peer review prior to being published. (https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1.full)
Earlier this week, Axios reported a new study (https://www.wnd.com/2021/08/stunning-study-pfizer-vaccine-42-effective/) by the Mayo Clinic found the Pfizer mRNA vaccine was only 42% effective against infection in July in the clinic's home state of Minnesota, when the delta variant became dominant.
The authors of the Japanese study on the lambda variant noted that at least 60% of Chile's population had received at least one dose of a COVID-19 vaccine in the spring.
"Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021, suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination," the researchers warn.
Currently, the lambda variant comprises only one-tenth of 1% of the cases in the U.S. so far.
"In addition to increasing viral infectivity, the Delta variant exhibits higher resistance to the vaccine-induced neutralization," the authors said. "Similarly, here we showed that the Lambda variant equips not only increased infectivity but also resistance against antiviral immunity."
Chile's vaccine campaign relied mostly on the Sinovac Biotech vaccine, which, like the Johnson & Johnson vaccine, uses a more traditional virus-based technology to produce antibodies.
Pfizer and Moderna use the Messenger RNA (mRNA) technology in which cells are instructed to make the S protein found on the surface of the COVID-19 virus.
In a July 27 vaccine briefing, the Centers for Disease Control and Prevention cited a July 3 pre-print study that concluded the mRNA vaccine in particular is thought to effectively neutralize the lambda variant.
None of the experimental vaccines, which are being administered under emergency use authorization, have been fully approved by the FDA.
Rest - https://www.wnd.com/2021/08/study-deadly-lambda-variant-vaccine-resistant/
Deadly Lambda variant could be neutralizing vaccines, new study says
As the US struggles to suppress the rapidly advancing coronavirus Delta variant, new evidence has emerged that the latest Lambda mutation — ravaging parts of South America — won’t be slowed by vaccines.
In a July 28 report appearing on bioRxiv, where the study awaits peer review prior to getting published, researchers in Japan are sounding the alarm on the C.37 variant, dubbed Lambda. And it’s proven just as virulent as Delta thanks to a similar mutation making them even more contagious.
The strain has been contained in 26 countries, including substantial outbreaks in Chile, Peru, Argentina and Ecuador.
“Notably, the vaccination rate in Chile is relatively high; the percentage of the people who received at least one dose of COVID-19 vaccine was [about] 60%,” the authors write.
“Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021, suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination,” they warn.
The Lambda variant is thought to have emerged somewhere in South America between November and December 2020, and has since turned up in countries throughout Europe, North America and a few more isolated cases in Asia, according to GISAID data.
Rest - https://nypost.com/2021/08/12/deadly-lambda-covid-19-variant-could-be-vaccine-resistant/
And then this study:
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Summary
SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America.
Highlights
Lambda S is highly infectious and T76I and L452Q are responsible for this property
Lambda S is more susceptible to an infection-enhancing antibody
RSYLTPGD246-253N, L452Q and F490S confer resistance to antiviral immunity
https://i.imgur.com/jjaUBpO.png
Introduction
During the pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has been diversified. As of July 2021, there are four variants of concerns (VOCs), Alpha [B.1.1.7 lineage; the lineage classification is based on Phylogenetic Assignment of Named Global Outbreak (PANGO): https://cov-lineages.org/resources/pangolin.html], Beta (B.1.351 lineage), Gamma (P.1 lineage) and Delta (B.1.617.2 lineage), and four variants of interests (VOIs), Eta (B.1.525 lineage), Iota (B.1.526 lineage), Kappa (B.1.617.1 lineage) and Lambda (C.37 lineage) (WHO, 2021a). These variants are considered to be the potential threats to the human society.
VOCs and VOIs harbor multiple mutations in their spike (S) protein and are relatively resistant to the neutralizing antibodies (NAbs) that are elicited in convalescent and vaccinated individuals (Chen et al., 2021; Collier et al., 2021; Garcia-Beltran et al., 2021; Hoffmann et al., 2021; Liu et al., 2021a; Liu et al., 2021b; Planas et al., 2021; Wall et al., 2021a; Wang et al., 2021a; Wang et al., 2021b). Because the receptor binding domain (RBD) of the SARS-CoV-2 S protein is immunodominant, mutations in this domain can lead to the immune evasion (Piccoli et al., 2020). Additionally, the mutations in the N-terminal domain (NTD) of the SARS-CoV-2 S protein are associated with the escape neutralization (McCallum et al., 2021). Moreover, the antibodies that enhance viral infectivity [enhancing antibodies (EAbs)] were detected in severe COVID-19 patients, and these EAbs target NTD (Li et al., 2021; Liu et al., 2021c). Because natural mutations in the S NTD crucially influence the sensitivity to antibodies (Gobeil et al., 2021), the accumulation of mutations in this domain is closely associated with the infection spread of VOCs and VOIs.
The Lambda variant (also known as the C.37 lineage) is the newest VOI (designated on June 14, 2021) (WHO, 2021a) and is currently spreading in South American countries such as Peru, Chile, Argentina, and Ecuador (WHO, 2021a). Based on the information data from the Global Initiative on Sharing All Influenza Data (GISAID) database (https://www.gisaid.org; as of June 29, 2021), the Lambda variant has been isolated in 26 countries. Notably, the vaccination rate in Chile is relatively high; the percentage of the people who received at least one dose of COVID-19 vaccine was ~60% on June 1, 2021 (https://ourworldindata.org/covid-vaccinations). A recent paper also suggested that the vaccines have effectively prevented COVID-19 in Chile (Jara et al., 2021). Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021 (WHO, 2021b), suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination. In this study, we reveal the evolutionary trait of the Lambda variant by molecular phylogenetic analysis. We further demonstrate that the RSYLTPGD246-253N mutation, a unique mutation in the NTD of the Lambda S protein, is responsible for the virological phenotype of the Lambda variant that can associate with the massive infection spread mainly in South American countries.
Rest - https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1.full
---
Study: Deadly lambda variant could be vaccine-resistant
Researchers sounding alarm on latest COVID mutation
As the United States struggles with the delta variant of the novel coronavirus, a new study finds that vaccines are ineffective against the lambda mutation that is ravaging parts of South America.
Researchers in Japan pointed out that the lambda variant, which first surfaced in Peru about a year ago, surged in Chile in the spring despite a high vaccination rate, the New York Post reported. (https://nypost.com/2021/08/12/deadly-lambda-covid-19-variant-could-be-vaccine-resistant/)
The study awaits peer review prior to being published. (https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1.full)
Earlier this week, Axios reported a new study (https://www.wnd.com/2021/08/stunning-study-pfizer-vaccine-42-effective/) by the Mayo Clinic found the Pfizer mRNA vaccine was only 42% effective against infection in July in the clinic's home state of Minnesota, when the delta variant became dominant.
The authors of the Japanese study on the lambda variant noted that at least 60% of Chile's population had received at least one dose of a COVID-19 vaccine in the spring.
"Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021, suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination," the researchers warn.
Currently, the lambda variant comprises only one-tenth of 1% of the cases in the U.S. so far.
"In addition to increasing viral infectivity, the Delta variant exhibits higher resistance to the vaccine-induced neutralization," the authors said. "Similarly, here we showed that the Lambda variant equips not only increased infectivity but also resistance against antiviral immunity."
Chile's vaccine campaign relied mostly on the Sinovac Biotech vaccine, which, like the Johnson & Johnson vaccine, uses a more traditional virus-based technology to produce antibodies.
Pfizer and Moderna use the Messenger RNA (mRNA) technology in which cells are instructed to make the S protein found on the surface of the COVID-19 virus.
In a July 27 vaccine briefing, the Centers for Disease Control and Prevention cited a July 3 pre-print study that concluded the mRNA vaccine in particular is thought to effectively neutralize the lambda variant.
None of the experimental vaccines, which are being administered under emergency use authorization, have been fully approved by the FDA.
Rest - https://www.wnd.com/2021/08/study-deadly-lambda-variant-vaccine-resistant/
Deadly Lambda variant could be neutralizing vaccines, new study says
As the US struggles to suppress the rapidly advancing coronavirus Delta variant, new evidence has emerged that the latest Lambda mutation — ravaging parts of South America — won’t be slowed by vaccines.
In a July 28 report appearing on bioRxiv, where the study awaits peer review prior to getting published, researchers in Japan are sounding the alarm on the C.37 variant, dubbed Lambda. And it’s proven just as virulent as Delta thanks to a similar mutation making them even more contagious.
The strain has been contained in 26 countries, including substantial outbreaks in Chile, Peru, Argentina and Ecuador.
“Notably, the vaccination rate in Chile is relatively high; the percentage of the people who received at least one dose of COVID-19 vaccine was [about] 60%,” the authors write.
“Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021, suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination,” they warn.
The Lambda variant is thought to have emerged somewhere in South America between November and December 2020, and has since turned up in countries throughout Europe, North America and a few more isolated cases in Asia, according to GISAID data.
Rest - https://nypost.com/2021/08/12/deadly-lambda-covid-19-variant-could-be-vaccine-resistant/
And then this study:
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Summary
SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America.
Highlights
Lambda S is highly infectious and T76I and L452Q are responsible for this property
Lambda S is more susceptible to an infection-enhancing antibody
RSYLTPGD246-253N, L452Q and F490S confer resistance to antiviral immunity
https://i.imgur.com/jjaUBpO.png
Introduction
During the pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has been diversified. As of July 2021, there are four variants of concerns (VOCs), Alpha [B.1.1.7 lineage; the lineage classification is based on Phylogenetic Assignment of Named Global Outbreak (PANGO): https://cov-lineages.org/resources/pangolin.html], Beta (B.1.351 lineage), Gamma (P.1 lineage) and Delta (B.1.617.2 lineage), and four variants of interests (VOIs), Eta (B.1.525 lineage), Iota (B.1.526 lineage), Kappa (B.1.617.1 lineage) and Lambda (C.37 lineage) (WHO, 2021a). These variants are considered to be the potential threats to the human society.
VOCs and VOIs harbor multiple mutations in their spike (S) protein and are relatively resistant to the neutralizing antibodies (NAbs) that are elicited in convalescent and vaccinated individuals (Chen et al., 2021; Collier et al., 2021; Garcia-Beltran et al., 2021; Hoffmann et al., 2021; Liu et al., 2021a; Liu et al., 2021b; Planas et al., 2021; Wall et al., 2021a; Wang et al., 2021a; Wang et al., 2021b). Because the receptor binding domain (RBD) of the SARS-CoV-2 S protein is immunodominant, mutations in this domain can lead to the immune evasion (Piccoli et al., 2020). Additionally, the mutations in the N-terminal domain (NTD) of the SARS-CoV-2 S protein are associated with the escape neutralization (McCallum et al., 2021). Moreover, the antibodies that enhance viral infectivity [enhancing antibodies (EAbs)] were detected in severe COVID-19 patients, and these EAbs target NTD (Li et al., 2021; Liu et al., 2021c). Because natural mutations in the S NTD crucially influence the sensitivity to antibodies (Gobeil et al., 2021), the accumulation of mutations in this domain is closely associated with the infection spread of VOCs and VOIs.
The Lambda variant (also known as the C.37 lineage) is the newest VOI (designated on June 14, 2021) (WHO, 2021a) and is currently spreading in South American countries such as Peru, Chile, Argentina, and Ecuador (WHO, 2021a). Based on the information data from the Global Initiative on Sharing All Influenza Data (GISAID) database (https://www.gisaid.org; as of June 29, 2021), the Lambda variant has been isolated in 26 countries. Notably, the vaccination rate in Chile is relatively high; the percentage of the people who received at least one dose of COVID-19 vaccine was ~60% on June 1, 2021 (https://ourworldindata.org/covid-vaccinations). A recent paper also suggested that the vaccines have effectively prevented COVID-19 in Chile (Jara et al., 2021). Nevertheless, a big COVID-19 surge has occurred in Chile in Spring 2021 (WHO, 2021b), suggesting that the Lambda variant is proficient in escaping from the antiviral immunity elicited by vaccination. In this study, we reveal the evolutionary trait of the Lambda variant by molecular phylogenetic analysis. We further demonstrate that the RSYLTPGD246-253N mutation, a unique mutation in the NTD of the Lambda S protein, is responsible for the virological phenotype of the Lambda variant that can associate with the massive infection spread mainly in South American countries.
Rest - https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1.full